Amirhossein Ashnaei - Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Zahra Farjami - Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Neshat Ebrahimi - Laboratory of Cedars-Sinai Medical Center, Los Angles, California, USA
Negar Khodaeinia - National Research Center of Genetic Engineering and Biotechnology (NIGEB), Department of Medical Genetics, Tehran, Iran

The document for the therapeutic effect of cannabinoid in the treatment of Multiple Sclerosis(MS) is enhancing but is not as yet persuasive.Also, most of the tests have reported no considerable effect, the large part of the evidence that supports a useful effect on spasticity and pain is based on the subjective measurement in tests was likely to be a problem. The accessible clinical trial study offer that the adverse side effects related to using cannabinoid based medical extracts are generally mild. However, several of these tests were review a period of months and it is possible that other adverse side effects, not shown in these short term data, could increase with long term use. Further there is no document to offer that their effects on balance and motor control, or immune function, maybe clinically considerable. Also, thereis reason to be concerned about the use of therapeutic cannabinoid people amenable to psychosis and by pregnant woman, given the enhancing document of their adverse effects on the embryo. Conclusion: The modest therapeutic effects of cannabinoid showed therisk of long term adverse side effects. There is reason to be continuous about their use in the treatment of MS